Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Conditions
Keywords
Newly Diagnosed AML, Secondary AML, Relapsed/Refractory AML, Relapsed/Refractory ALL, MDS
Brief summary
The purpose of this study is to assess the effects of CPX-351 on cardiac repolarization, assess plasma drug levels, asses serum copper levels, and assess drug levels in urine. Efficacy and Safety will be assessed in all patients enrolled to the study.
Detailed description
This study is an open-label, single-arm, Phase II, PK and pharmacodynamic (PD) trial of CPX-351 in patients with documented acute leukemia (AML or ALL) or MDS (IPSS score ≥ 1.5) and suitable for treatment with intensive chemotherapy. Each patient will be screened for hepatic impairment. Hepatic impairment will be assessed using the Child-Pugh system and only patients with a Child-Pugh score \<7 points will be eligible for this study. Patients will receive up to two inductions and four consolidation courses. Patients will be monitored for safety (early deaths, adverse events, metabolic changes, etc.) and efficacy (response for AML, ALL, and MDS) while on the study.
Interventions
DRUGCPX-351
Sponsors
Jazz Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Ability to understand and voluntarily sign an informed consent form * Age ≥ 18 to ≤ 80 years at the time of signing the informed consent form * Life expectancy of at least 3 months * Pathological confirmation by bone marrow documenting the following: * Newly Diagnosed De novo AML according to WHO criteria except for Acute Promyelocytic Leukemia or patients with known favorable cytogenetics (see exclusion) * Newly Diagnosed Secondary AML age \<60 years and ≥76 to 80 years, defined as having a history of an antecedent hematologic disorder (myelodysplastic syndromes \[MDS\], myeloproliferative disease \[MPD\]or history of cytotoxic treatment for non-hematologic malignancy) * Patients with relapsed/refractory AML regardless of cytogenetic risk * Patients with relapsed/refractory ALL * Patients with MDS (IPSS score ≥ 1.5) * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 * Able to adhere to the study visit schedule and other protocol requirements * Laboratory values fulfilling the following: * Serum Creatinine ≤ 2.0mg/dL * Hepatic function with a score of \< 7 points according to the Child-Pugh System * Serum alanine aminotransferase or aspartate aminotransferase \< 3 times the ULN. Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss. * Cardiac ejection fraction ≥50% by ECHO or MUGA * Screening and Baseline QTcF (Fridericia's) less than 470 msec * Patients with second malignancies in remission may be eligible if there is clinical evidence of disease stability for a period of greater than 6 months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are eligible. * All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.
Exclusion criteria
* Patients eligible for participation in Study CLTR0310-301 (Phase III study of CPX-351 NCT01696084) or who have already participated in that study are not eligible for this study. * Patients taking medications known to prolong the QTc interval directly or that interact pharmacodynamically with medicines to prolong the QTc interval. * Rhythm abnormalities (other than sinus bradycardia with HR \< 50 bpm) * AV block (other than 1o AV Block with PR \> 200 msec) * Bundle branch block or QRS ≥ 120 msec * Abnormal T wave morphology (other than slight flattening) * Pathological U waves * Other QRS or T/U morphology preventing accurate determination of QT interval * Patients with unexplained syncope, history of or known risk factors for torsade des pointes, including congenital long QT syndrome, or family history of LQTS. * Patients with history of and/or current evidence of myocardial impairment (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging) * Newly diagnosed patients with Acute promyelocytic leukemia \[t(15;17)\] or favorable cytogenetics, including t(8;21) or inv16 * Clinical evidence of active CNS leukemic involvement * Chemotherapy or other investigational anticancer therapeutic drugs within 1 week prior to study entry unless AEs have resolved and there is no interference with the assessment of efficacy or safety; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to 12 hours before study entry. Patients with prior bone marrow or stem cell transplant, considered for inclusion, should be discussed with the medical monitor first. * Any serious medical condition or psychiatric illness that would prevent the patient from providing informed consent * Patients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent) * Active or uncontrolled infection. Patients with any infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ≥72 hrs. Patients with fevers believed to be due to leukemia or MDS are eligible provided a thorough infection work-up is negative and the patient is clinically and hemodynamically stable. * Pregnant or lactating women * Hypersensitivity to cytarabine, daunorubicin or liposomal products * History of Wilson's disease or other copper-related metabolic disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | 21 days | Time-matched QTcF Changes From Baseline after the start of first infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Copper Levels Change From Baseline | During 1st induction (up to 5 days) | Change from Baseline to Induction 1, Day 5 |
| Complete Response Rate | Following 1st induction, following 2nd induction if applicable | — |
| Tmax | Induction 1, Day 5 | — |
| Cmax | Induction 1, Day 5 | — |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| CPX-351 Single Arm Study (Patients may receive up to 2 Inductions and up to 4 Consolidations):
Induction 1: CPX-351 will be given intravenously at 100units/m2 on days 1, 3, and 5 over a 90 minute infusion.
Induction 2: CPX-351 will be given intravenously at 100units/m2 on days 1 and 3 over a 90 minute infusion.
Consolidations: CPX-351 will be given intravenously at 65units/m2 on days 1 and 3 over a 90 minute infusion.
CPX-351 | 26 |
| Total | 26 |
Baseline characteristics
| Characteristic | CPX-351 |
|---|---|
| Age, Continuous | 65.2 years STANDARD_DEVIATION 9.31 |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 26 / 26 |
| serious Total, serious adverse events | 8 / 26 |
Outcome results
Primary
Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF)
Time-matched QTcF Changes From Baseline after the start of first infusion
Time frame: 21 days
Population: All subjects who received any dose of study drug and had at least 1 time-matched change from baseline in ECG parameters.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CPX-351 | Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | Time-point 0.75 h | 0.6 msecs | Standard Deviation 15.13 |
| CPX-351 | Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | Time-point 1.5 h | -1.2 msecs | Standard Deviation 13.3 |
| CPX-351 | Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | Time-point 2 h | 4.3 msecs | Standard Deviation 15.96 |
| CPX-351 | Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | Time-point 3 h | 5.3 msecs | Standard Deviation 15.17 |
| CPX-351 | Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | Time-point 4 h | 8.0 msecs | Standard Deviation 11.69 |
| CPX-351 | Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | Time-point 6 h | -0.1 msecs | Standard Deviation 11.24 |
| CPX-351 | Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | Time-point 8 h | 4.8 msecs | Standard Deviation 8.52 |
| CPX-351 | Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | Time-point 12 h | -2.3 msecs | Standard Deviation 10.43 |
| CPX-351 | Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) | Time-point 24 h | -6.2 msecs | Standard Deviation 13.91 |
Secondary
Cmax
Time frame: Induction 1, Day 5
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CPX-351 | Cmax | Cytarabine | 62200 ng/ml | Standard Deviation 20900 |
| CPX-351 | Cmax | Ara-U | 1240 ng/ml | Standard Deviation 252 |
| CPX-351 | Cmax | Daunorubicin | 26000 ng/ml | Standard Deviation 8510 |
| CPX-351 | Cmax | Daunorubicinol | 147 ng/ml | Standard Deviation 52.3 |
Secondary
Complete Response Rate
Time frame: Following 1st induction, following 2nd induction if applicable
Population: Efficacy population: All subjects who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CPX-351 | Complete Response Rate | 8 Participants |
Secondary
Serum Copper Levels Change From Baseline
Change from Baseline to Induction 1, Day 5
Time frame: During 1st induction (up to 5 days)
Population: All subjects who received at least 1 dose of study drug and copper data were collected.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| CPX-351 | Serum Copper Levels Change From Baseline | 64.95 μg/dL | Standard Deviation 51.119 |
Secondary
Tmax
Time frame: Induction 1, Day 5
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| CPX-351 | Tmax | Cytarabine | 2.00 hours |
| CPX-351 | Tmax | Ara-U | 8.00 hours |
| CPX-351 | Tmax | Daunorubicin | 2.00 hours |
| CPX-351 | Tmax | Daunorubicinol | 26.00 hours |